Liver ITO cell separation-cryopreservation-resuscitation ready-to-use system construction method and application

By optimizing the isolation and frozen method of ITO cells, combined with the gel frozen solution without allergen, the rapid activation of ITO cells and the release of growth factors are achieved, and the application of ITO cells in wound healing is solved, which significantly promotes the Skin repair and hair growth reduce separation costs and operational complexity.

CN119081992APending Publication Date: 2024-12-06NORTHWESTERN POLYTECHNICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411099385.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-12
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The prior art is difficult to effectively isolate and frozen large mammalian liver ITO cells, and the frozen solution is not suitable for direct use in cell culture after resuscitation, which affects its application in wound healing.

Method used

A ready-to-use system for liver ITO cells is designed to separate, frozen and resuscitate liver ITO cells. By optimizing the lossless high-purity separation method and the allergen-free gel cell frozen solution, the rapid activation of ITO cells and the release of growth factors are achieved. Supports wound repair and hair growth.

Benefits of technology

The isolation and frozen storage of high-vibration ITO cells is achieved, providing a product that can be used directly for wound therapy, significantly promoting wound healing and hair regeneration, reducing separation costs and operational complexity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119081992A_ABST
    Figure CN119081992A_ABST
Patent Text Reader

Abstract

The invention discloses a construction method and application of a liver ITO cell separation-cryopreservation-resuscitation ready-to-use system, and relates to the field of cell therapy of a biological medicine technology. The method comprises the following steps: separating unactivated primary ITO cells from the liver of a mammal; the method comprises the following steps: fully mixing ITO cells with a ready-to-use cell cryopreservation solution, and storing in a liquid nitrogen environment after programmed cooling; when treatment requirements exist, the cryopreserved primary ITO cells are rapidly reheated to be in a liquid state, and the obtained high-activity ITO cells and the cell cryopreservation liquid are directly applied to various wound epidermis or deep areas. According to the invention, the repair of various wounds and the regeneration of hair follicles are promoted by utilizing a wet healing environment formed by the ready-to-use cell cryopreservation liquid in a wound area, growth factors continuously and massively released by ITO cells in a rapid activation process in the wound area, and vitamin A released by self necrosis and rupture of the ITO cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a method for constructing a ready-to-use system for separation-cryopreservation-resuscitation of liver ITO cells and applications thereof. Background Art

[0002] The liver is one of the organs with the strongest regenerative ability in the human body. Even if 70-80% of the liver is removed, the remaining liver cells can still regenerate to their original size. It is currently believed that liver regeneration is achieved by regulating growth factors to promote the division and proliferation of liver cells themselves. This mechanism not only reveals the mechanism of liver self-repair, but also has important application value in clinical practice, bringing new inspiration to the treatment and rehabilitation of related diseases. ITO cells belong to non-parenchymal pericytes, also known as fat storage cells. They are located in the Disse subendothelial cavity of the liver and are rich in lipid droplets, which store more than 80% of the vitamin A in the human body. In normal livers, ITO cells are rich in a large number of lipid droplets and are in a dormant state in the liver. Their main function in the body is to store vitamin A and protect liver cells. When the liver is damaged or stimulated by external factors, ITO cells are automatically activated and begin to differentiate. This differentiation process lasts for 1-2 weeks, and finally differentiates into fibroblasts. During this period, a series of paracrine mechanisms are regulated to promote liver repair. For example: when the liver is damaged, ITO cells can secrete hepatocyte growth factor, promote hepatocyte proliferation, and help restore liver morphology. The vitamin A in them can also maintain the stemness of hepatocytes and enhance the ability of hepatocytes to divide and proliferate. In chronic liver disease, ITO cells release inflammatory chemokines during activation to promote fibrosis and cancer progression. This feature has important clinical significance in the field of regenerative medicine. However, there has been no use of large mammalian liver ITO cells for the regeneration and repair of human wounds, nor is there a method for isolating large mammalian liver ITO. If the separated primary cells are directly applied to the wound, the process preparation cycle is long and the links are complicated. Therefore, it is difficult to meet various treatment application scenarios, and large-scale cell cryopreservation is required for storage and backup. However, conventional cryopreservation Existing cell freezing solutions are generally not suitable for direct cell culture after cell thawing and need to be discarded. The main reason is that the dimethyl sulfoxide (DMSO) and other ingredients contained in it protect cells from freezing damage during the freezing process and ensure that the cells can restore their original physiological functions and biological characteristics after thawing. However, when cells need to be cultured, they need a growth environment that can support their differentiation and metabolism, which usually includes appropriate culture media, growth factors, hormones and other nutrients, which may not be sufficient or completely suitable for cell culture needs in cell freezing solutions. Therefore, we need to design a solution that can maintain the activity of frozen cells to the greatest extent while meeting the requirements of short-term cell growth. The freezing solution does not contain allergens or cytotoxic substances, can be directly used on skin wounds, and can synergistically promote tissue regeneration and accelerate wound healing. Summary of the invention

[0003] In view of the deficiencies in the above-mentioned background technology, the present invention mainly solves three technical problems: 1. Designing a sterile and efficient separation process for large mammalian liver ITO cells; 2. Designing a special freezing solution that can be used for both freezing and culturing ITO cells, which can form the basic conditions required for moist healing of wounds and can effectively support the rapid activation of ITO cells in the wound area and release a large number of growth factors; 3. For the first time, it is proposed and adopted that liver ITO cell activation promotes moist healing of various types of wounds.

[0004] The present invention provides a method for constructing a ready-to-use system for separation-cryopreservation-resuscitation of liver ITO cells and its application. It is applied to the fields of regenerative medicine such as wound healing and hair regeneration. By optimizing the non-destructive high-purity separation of liver ITO cells of large mammals and the development of gel cell cryopreservation solution without allergens, high-viability ITO cells can be obtained by achieving conventional rapid cell rewarming operations and directly used for wound treatment. Liver ITO cells are used in the cryopreservation solution to complete rapid activation of ITO cells and release of growth factors, thereby promoting various types of wound repair and hair follicle regeneration. The present invention aims to provide a separation method that is non-damaging to cells, has high separation efficiency, strong operability and low cost, and a ready-to-use cell cryopreservation solution that simultaneously has both cell cryopreservation and culture, and finally uses the characteristics of automatic activation of ITO cells to provide a new treatment method for promoting wound repair and hair growth.

[0005] The first object of the present invention is to provide a method for constructing a ready-to-use system for separation-freezing-recovery of liver ITO cells, comprising the following steps: Highly viable unactivated ITO cells were isolated from mammalian liver; The ITO cells were fully mixed with the ready-to-use cell freezing solution, programmed to cool, and stored in liquid nitrogen; Rapidly rewarming the frozen ITO cells to a liquid state can obtain a highly active and unactivated ITO cell suspension; Wherein, the cell freezing solution is prepared according to the following steps: Under sterile conditions, a certain amount of high-glucose culture medium and insulin were weighed, and sterile water was added to a certain volume to prepare a 4X concentration mixed solution, which is the mix1 solution; Add an equal volume of 4X concentration propylene glycol (8%) to the 4X concentration mix1 solution to obtain a 2X concentration mix2 solution; Mix 2X concentration of mix2 solution and 2X concentration of sodium carboxymethyl cellulose (3%), and stir to mix evenly, and adjust the pH value to 6.9-7.2 to obtain 1X concentration of mix3 solution; The 1X concentration mix3 solution was sterilized and mixed with an equal volume of liver matrix gel to obtain the target cell freezing solution.

[0006] Preferably, the ITO cells are isolated according to the following steps: Obtain mammalian liver with portal vein and inferior vena cava preserved in a sterile environment; The mammal liver was cannulated in the portal vein in a sterile operating room, and preheated saline was perfused with heparin. The perfusion was continued to completely remove the red blood cells in the liver until the liver appeared yellow-white; The liver without red blood cells was perfused with enzyme digestion solution at 37°C until the liver became soft and inelastic, and then broken in cell dispersion solution to obtain liver slurry; The liver slurry was continuously perfused with cells at 4°C and filtered, and the filtered suspension was collected; The filtered suspension was centrifuged, resuspended and fixed to volume to obtain ITO cells.

[0007] Preferably, the cell suspension is centrifuged, resuspended, and fixed to volume, comprising: The filtered suspension was centrifuged at 500 rpm / min for 10 min, the lower layer of cells was removed and resuspended with D-Hanks solution, then centrifuged at 500 rpm / min for 10 min, the supernatant was removed, and then centrifuged at 1750 rpm / min for 10 min, the lower layer of sediment was removed and resuspended with serum-free DMEM culture medium, and the volume was fixed to obtain a cell suspension; 60% percoll and 30% percoll were added to the bottom of a 50 ml centrifuge tube, and finally the cell suspension was added and centrifuged. In the obtained system, the upper layer of 30% percoll was the obtained ITO cells. The 30% or 60% percoll is prepared by adding 10 ml of 10% sodium chloride to 100 ml of percoll to prepare a 100% stock solution, and using 0.9% physiological saline to prepare a target concentration of 30% or 60%.

[0008] Preferably, the enzyme digestion solution is prepared by adding type IV collagenase and pronase E to a D-hanks solution, mixing evenly, adjusting the pH value to 7.3, and filtering and sterilizing, wherein the mass ratio of type IV collagenase to pronase E is 1:2; The cell dispersion is prepared by adding type IV collagenase, pronase E and DNase I to D-hanks solution, mixing evenly and filtering for sterilization, wherein the mass ratio of type IV collagenase, pronase E and DNase I is 10:4:1.

[0009] Preferably, the liver matrix gel is prepared according to the following steps: The filtered suspension was centrifuged at 500 rpm / min for 10 min, the supernatant was taken, and the cell debris was removed by filtration and centrifugation. The liver matrix gel was obtained by concentration, filtered and sterilized for later use.

[0010] Preferably, when preparing the target cell freezing solution, the volume ratio of the high-glucose culture medium, insulin, sodium carboxymethyl cellulose and liver matrix gel is 1:1:1:1; the concentration of 4X insulin is 0.04 mg / ml.

[0011] Preferably, 4X high glucose medium is prepared from the following components: Calcium chloride dihydrate 1000~1100mg / L, L-serine 160~170mg / L, ferric nitrate nonahydrate 0.3~0.5mg / L, L-threonine 350~400mg / L, potassium chloride 1500~2000mg / L, L-tryptophan 50~80mg / L, anhydrous magnesium sulfate 350~400mg / L, L-tyrosine 260~300mg / L, sodium chloride 20000~30000mg / L, L-valine 350~400mg / L, anhydrous sodium dihydrogen phosphate 400~450mg / L, D-calcium pantothenate 12~18mg / L, succinic acid 280~320mg / L, choline bitartrate 25.5~30.3mg / L, sodium succinate 380~410mg / L, folic acid 13~18mg / L, L-arginine hydrochloride 310~350mg / L, inositol 26.6~30.3mg / L, L-cystine hydrochloride 160~200mg / L, niacinamide 14~17mg / L, glycine 4500~5000mg / L, riboflavin 6.0~7.0mg / L, L-histidine hydrochloride 150~170mg / L, thiamine hydrochloride 12~20mg / L, L-isoleucine 400~450mg / L, pyridoxine hydrochloride 12~18mg / L, L-leucine 400~450mg / L, glucose 3700~4200mg / L, L-lysine hydrochloride 550~600mg / L, sodium pyruvate 400~450mg / L, L-methionine 100~150mg / L, L-phenylalanine 240~280mg / L.

[0012] Preferably, the concentration of 4X propylene glycol is 8% of the 4X stock solution concentration; the concentration of 2X sodium carboxymethyl cellulose stock solution is 3%, and the final concentrations after preparation are 2% and 1.5% respectively.

[0013] The second object of the present invention is to provide a cell freezing solution containing ITO.

[0014] The third object of the present invention is to provide a complete process scheme for promoting the moist healing of various wound surfaces by activating liver ITO cells.

[0015] Compared with the prior art, the present invention has the following beneficial effects: The present invention provides a method for constructing a ready-to-use system for separation-freezing-recovery of liver ITO cells and its application. The present invention uses a cryopreservation solution rich in highly active ITO cells to be directly placed locally on the wound surface, and uses various growth-promoting factors produced by ITO cells during the local activation process of the wound surface to achieve the medical efficacy of promoting wound healing and hair regeneration. The liver matrix components contained in the cryopreservation solution and the exogenously added carboxymethyl dextran not only play a role in protecting the cell activity of the frozen ITO, but also provide a moist environment to promote ITO cell activation and assist wound healing. In the future, this product will be used for various types of acute and chronic superficial and deep wounds such as large-area burns, cuts, pressure sores, diabetic foot, etc. on the human body, and at the same time has a certain therapeutic effect on hair growth inhibition caused by hair follicle damage. BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 is the proportion of cells that underwent apoptosis after cell recovery.

[0017] Figure 2 It is the differentiation time after cell recovery.

[0018] Figure 3 It is the survival status after wound injection. DETAILED DESCRIPTION

[0019] In order to enable those skilled in the art to better understand and implement the technical solution of the present invention, the present invention is further described below in conjunction with specific embodiments and drawings, but the embodiments are not intended to limit the present invention.

[0020] According to previous studies, the number of ITO cells that can be isolated from the intact liver of adult dairy goats is about 1×10 10 On the basis of the traditional ITO cell Friedman extraction method, the separation process, separation equipment and related digestive enzymes are improved and optimized based on the characteristics of large mammals to achieve the goal of controlling separation costs, improving separation efficiency and obtaining highly active liver ITO cells. In order to facilitate clinical application, a gel-like cell freezing solution without allergens has also been developed, and the separated liver ITO cells can be frozen without loss, and high-activity ITO cells can be obtained by conventional rapid thawing and can be directly used on various wounds. This new type of freezing solution can construct a moist environment, support the growth of resuscitated liver ITO cells, and accelerate the completion of the cell activation process based on the freezing solution. Necrotic and ruptured ITO cells can also release a large amount of vitamin A, further promoting the growth and differentiation of the wound.

[0021] The liver is one of the organs with the strongest regenerative ability in the human body. Even if 70-80% of the liver is removed, the remaining liver cells can still regenerate to their original size. This biological characteristic has important implications in the field of tissue regeneration and wound repair. Our study found that the unactivated ITO cells in the liver are the main participants in liver cell regeneration. The relevant mechanism is related to the fact that the lipid droplets in the unactivated ITO cells are rich in 80% of the human vitamin A and a large amount of growth factors are released during the activation process. Therefore, in order to facilitate this liver self-repair and regeneration mechanism and apply it to wound regeneration first, we optimized the efficient and non-destructive separation and purification method of large mammalian liver ITO cells, developed a new cell cryopreservation solution containing liver matrix gel without allergens, and finally successfully established a new product rich in highly active ITO cells that can be directly applied to wound treatment for local wound treatment. In the field of mouse skin wound healing and hair regeneration medicine, it was confirmed that the product has a significant effect on promoting wound healing and hair regeneration. The present invention prepares a cryopreservation solution rich in highly active primary liver ITO cells by taking advantage of the biological characteristics of the ITO cell activation process, and can be directly applied to various wounds after the cells are quickly rewarmed, and the growth-promoting factors actively released during the ITO activation process are used to accelerate wound healing; and the liver matrix components contained in the cryopreservation solution and the exogenously added carboxymethyl glucose also have moisturizing, anti-inflammatory and ITO growth and differentiation promoting effects. In the future, this product can be used for various acute and chronic wounds such as human body burns, cuts, pressure sores, diabetic foot, and related hair follicle damage-induced hair growth inhibition.

[0022] In order to achieve the above object, the present invention provides a method for constructing a ready-to-use system for separation-cryopreservation-recovery of liver ITO cells, comprising the following steps: Highly viable unactivated ITO cells were isolated from mammalian liver; The ITO cells were fully mixed with the ready-to-use cell freezing solution, programmed to cool, and stored in liquid nitrogen; By quickly rewarming the frozen ITO cells to a liquid state, a highly active and unactivated ITO cell suspension can be obtained and directly used for medical treatment; Wherein, the cell freezing solution is prepared according to the following steps: Under sterile conditions, a certain amount of high-glucose culture medium, insulin, sodium carboxymethyl cellulose and liver matrix gel were weighed, and sterile water was added to a certain volume, and equal volumes of target cell freezing solution were sequentially prepared; Under sterile conditions, a certain amount of high-glucose culture medium and insulin were weighed, and sterile water was added to a certain volume to prepare a 4X concentration mixed solution, which is the mix1 solution; Add an equal volume of 4X concentration propylene glycol (8%) to the 4X concentration mix1 solution to obtain a 2X concentration mix2 solution; Mix 2X concentration of mix2 solution and 2X concentration of sodium carboxymethyl cellulose (3%), and stir to mix evenly, and adjust the pH value to 6.9-7.2 to obtain 1X concentration of mix3 solution; The 1X concentration mix3 solution was sterilized and mixed with an equal volume of liver matrix gel to obtain the target cell freezing solution.

[0023] The mammalian liver ITO cells are isolated according to the following steps: Obtain mammalian liver with portal vein and inferior vena cava preserved in a sterile environment; The mammal liver was cannulated in the portal vein in a sterile operating room, and preheated saline was perfused with heparin. The perfusion was continued to completely remove the red blood cells in the liver until the liver appeared yellow-white; The liver without red blood cells was perfused with enzyme digestion solution at 37°C until the liver became soft and inelastic, and then broken in cell dispersion solution to obtain liver slurry; The liver slurry was continuously perfused with cells at 4°C and filtered, and the filtered suspension was collected; The filtered suspension was centrifuged, resuspended and fixed to volume to obtain ITO cells.

[0024] The enzyme digestion solution is prepared by adding type IV collagenase and pronase E to a D-hanks solution, mixing them evenly, adjusting the pH value to 7.3, and filtering and sterilizing, wherein the mass ratio of type IV collagenase to pronase E is 1:2; The cell dispersion is prepared by adding type IV collagenase, pronase E and DNase I to D-hanks solution, mixing evenly and filtering for sterilization, wherein the mass ratio of type IV collagenase, pronase E and DNase I is 10:4:1.

[0025] Specifically, the cell suspension is centrifuged, resuspended, and fixed to volume, including: The filtered suspension was centrifuged at 500 rpm / min for 10 min, the lower layer of cells was removed and resuspended with D-Hanks solution, then centrifuged at 500 rpm / min for 10 min, the supernatant was removed, and then centrifuged at 1750 rpm / min for 10 min, the lower layer of sediment was removed and resuspended with serum-free DMEM culture medium, and the volume was fixed to obtain a cell suspension; 60% percoll and 30% percoll were added to the bottom of a 50 ml centrifuge tube, and finally the cell suspension was added and centrifuged. In the obtained system, the upper layer of 30% percoll was the obtained ITO cells. The 30% or 60% percoll is prepared by adding 10 ml of 10% sodium chloride to 100 ml of percoll to prepare a 100% stock solution, and using 0.9% physiological saline to prepare a target concentration of 30% or 60%.

[0026] Wherein, the liver matrix gel is prepared according to the following steps: The filtered suspension was centrifuged at 500 rpm / min for 10 min, the supernatant was collected, filtered and centrifuged to remove cell debris, and liver matrix gel was obtained by concentration.

[0027] When preparing the target mixed cryopreservation solution, the high glucose culture medium, insulin, sodium carboxymethyl cellulose and liver matrix gel are mixed in equal volumes until the 1X target cryopreservation solution is completed. The final concentration of insulin is 0.01 mg / ml, the final concentration of propylene glycol is 2%, and the final concentration of sodium carboxymethyl cellulose is 1.5%. The 4X high glucose medium is prepared from the following components: Calcium chloride dihydrate 1000~1100mg / L, L-serine 160~170mg / L, ferric nitrate nonahydrate 0.3~0.5mg / L, L-threonine 350~400mg / L, potassium chloride 1500~2000mg / L, L-tryptophan 50~80mg / L, anhydrous magnesium sulfate 350~400mg / L, L-tyrosine 260~300mg / L, sodium chloride 20000~30000mg / L, L-valine 350~400mg / L, anhydrous sodium dihydrogen phosphate 400~450mg / L, D-calcium pantothenate 12~18mg / L, succinic acid 280~320mg / L, choline bitartrate 25.5~30.3mg / L, sodium succinate 380~410mg / L, folic acid 13~18mg / L, L-arginine hydrochloride 310~350mg / L, inositol 26.6~30.3mg / L, L-cystine hydrochloride 160~200mg / L, niacinamide 14~17mg / L, glycine 4500~5000mg / L, riboflavin 6.0~7.0mg / L, L-histidine hydrochloride 150~170mg / L, thiamine hydrochloride 12~20mg / L, L-isoleucine 400~450mg / L, pyridoxine hydrochloride 12~18mg / L, L-leucine 400~450mg / L, glucose 3700~4200mg / L, L-lysine hydrochloride 550~600mg / L, sodium pyruvate 400~450mg / L, L-methionine 100~150mg / L, L-phenylalanine 240~280mg / L.

[0028] Preferably, 4X high glucose medium is prepared from the following components: 1060 mg / L calcium chloride dihydrate, 168 mg / L L-serine, 0.4 mg / L ferric nitrate nonahydrate, 380 mg / L L-threonine, 1600 mg / L potassium chloride, 64 mg / L L-tryptophan, 390 mg / L anhydrous magnesium sulfate, 288 mg / L L-tyrosine, 25600 mg / L sodium chloride, 376 mg / L L-valine, 436 mg / L anhydrous sodium dihydrogen phosphate, 16 mg / L D-calcium pantothenate, 300 mg / L succinic acid, 28.8 mg / L choline bitartrate, 400 mg / L sodium succinate , folic acid 16mg / L, L-arginine hydrochloride 336mg / L, inositol 28.8mg / L, L-cystine hydrochloride 189mg / L, niacinamide 16mg / L, glycine 4800mg / L, riboflavin 6.4mg / L, L-histidine hydrochloride 168mg / L, thiamine hydrochloride 16mg / L, L-isoleucine 420mg / L, pyridoxine hydrochloride 16mg / L, L-leucine 420mg / L, glucose 4000mg / L, L-lysine hydrochloride 584mg / L, sodium pyruvate 440mg / L, L-methionine 120mg / L, L-phenylalanine 264mg / L.

[0029] Preferably, the 4X concentration of insulin is 0.01 mg / ml, the 4X concentration of polyol is 8%, and the 2X concentration of sodium carboxymethylcellulose is 3%.

[0030] In one embodiment, a method for constructing a ready-to-use system for separation-freezing-recovery of liver ITO cells comprises the following steps: 1. Highly viable and sterile separation and purification of primary ITO cells from large mammal livers: 1.1 Non-destructive separation and purification of ITO cells from large mammals. The following method uses dairy goat liver as an example: (1) After routine disinfection and laying of disposable sterile towels, the liver of a dairy goat with the portal vein and inferior vena cava intact was obtained in a sterile environment; (2) Perform portal vein cannulation in a sterile operating room and perfuse the liver with preheated saline + heparin. Continue to perfuse the liver to completely remove red blood cells until the liver turns yellow-white. (3) Move the liver to a sterile clean bench, set to 37°C, and perfuse with enzyme digestion solution until the liver becomes soft and inelastic (10-20 minutes); (4) In a sterile operating room, use a cell dispersion solution and a small slow-speed crushing mixer to continuously crush the liver (10-20 minutes, 37°C) until the liver becomes a paste; (5) The resulting paste-like cell suspension is continuously irrigated through a sieve (400 mesh) using a low-temperature D-Hanks filter (4°C), and the filtered cell suspension at the bottom layer is collected; (6) Centrifuge the cell suspension at low speed (500 rpm / min, 10 min) and discard the supernatant. Remove the lower layer of cells and resuspend them in D-Hanks. (7) Ultra-low speed centrifugation, take the supernatant (500 rpm / min, 10 min); low speed centrifugation, discard the supernatant (1750 rpm / min, 10 min), resuspend in low-temperature serum-free DMEM culture medium, and adjust the volume of the resuspended cell suspension to 5×10 7 Cell system aliquoting; (8) Add 60% Percoll and then 30% Percoll to the bottom of a 50 ml centrifuge tube, and finally slowly add the above cell suspension and centrifuge; (9) In the obtained system, the upper layer of 30% percoll is the target ITO cells, about 1×10 7 indivual.

[0031] 1.2 Collagenase and related solutions are prepared as follows: (1) The enzyme digestion solution (Hanks solution I): 250 mg of type IV collagenase (final concentration of 0.05%), 500 mg of pronase E (final concentration of 0.1%), add 500 ml of D-hanks solution to dissolve, adjust to pH 7.3, filter and sterilize, and store after aliquoting.

[0032] (2) The cell dispersion solution (Hanks solution II): 250 mg of type IV collagenase (final concentration of 0.05%), 100 mg of pronase E (final concentration of 0.02%), and 25 mg of DNase I, dissolved in 500 ml of D-Hanks solution, filtered and sterilized, and stored in aliquots. Complete separation of cells and large tissue blocks is the key to obtaining pure and active ITO cells.

[0033] (3) The 30% percoll density gradient centrifuge: 100ml of 10% sodium chloride is added to 100ml percoll to prepare a 100% stock solution, and 0.9% saline is used to prepare a 30% target concentration, 100mg / 500mL, before use. The prepared percoll centrifuge allows the target ITO cells to be completely separated according to the density gradient, and almost no other cells exist in this density range, further improving the purity of ITO cells.

[0034] 2. Preparation of a novel cell freezing medium containing liver matrix gel (allergen-free / DMSO-free) 2.1 Formula of allergen-free gel cell freezing solution: (1) High glucose culture medium (DMEM), specifically including the following components: calcium chloride dihydrate 265 mg / L, L-serine 42 mg / L, ferric nitrate nonahydrate 0.1 mg / L, L-threonine 95 mg / L, potassium chloride 400 mg / L, L-tryptophan 16 mg / L, anhydrous magnesium sulfate 97.67 mg / L, L-tyrosine 72 mg / L, sodium chloride 6400 mg / L, L-valine 94 mg / L, anhydrous sodium dihydrogen phosphate 109 mg / L, D-calcium pantothenate 4 mg / L, succinic acid 75 mg / L, choline bitartrate 7.2 mg / L, sodium succinate 100 mg / L, folic acid 4mg / L, L-arginine hydrochloride 84mg / L, inositol 7.2mg / L, L-cystine hydrochloride 63mg / L, niacinamide 4mg / L, glycine 30mg / L, riboflavin 0.4mg / L, L-hydrochloride group 42mg / L, thiamine hydrochloride 4mg / L, L-isoleucine 105mg / L, pyridoxine hydrochloride 4mg / L, L-leucine 105mg / L, glucose 1000mg / L, L-lysine hydrochloride 146mg / L, sodium pyruvate 110mg / L, L-methionine 30mg / L, L-phenylalanine 66mg / L; (2) Insulin (0.01 mg / ml); (3) Organic macromolecular compound (1.5% sodium carboxymethyl cellulose); (4) Propylene glycol (2%) (4) Dairy goat liver matrix gel.

[0035] 2.2 Preparation of goat matrix gel (1) Obtain the supernatant discarded in step 6 of step 1.1, and filter and centrifuge to remove cell debris; (2) Concentrate goat liver matrix gel, filter and sterilize, and store at -80°C for future use.

[0036] 3. Preparation of cryopreservation solution and storage and application of ready-to-use system for ITO cell cryopreservation and thawing 3.1 Preparation of allergen-free cell cryopreservation solution containing liver matrix gel (1) Under sterile conditions, weigh a certain amount of high-glucose culture medium, insulin, sodium carboxymethyl cellulose, and liver matrix gel, add sterile water to a certain volume, and sequentially prepare the target cell freezing solution with equal volumes; (2) Under sterile conditions, weigh a certain amount of high-glucose culture medium and insulin, add sterile water to a certain volume, and prepare a 4X concentration mixed solution, which is Mix 1; (3) Add an equal volume of 4X concentration propylene glycol (8%) to the 4X concentration mix1 solution to obtain a 2X concentration mix2 solution; (4) Mix 2X concentration of mix2 solution and 2X concentration of sodium carboxymethyl cellulose (3%) and stir to mix evenly, adjust the pH value to 6.9-7.2, and obtain 1X concentration of mix3 solution; (5) Sterile filter the mix3 solution using a 0.22 μm filter; (6) Mix with goat liver matrix gel and store at -80 degrees until used.

[0037] 3.2 Preparation and clinical application of the ready-to-use system for cryopreservation and thawing of ITO cells (1) Take the successfully isolated ITO cells and mix them thoroughly with 2 ml of cell freezing solution (final concentration 1×10 7 / 2ml), programmed cooling to -80℃, and long-term storage in liquid nitrogen.

[0038] (2) The cryopreserved ITO cells are routinely and quickly thawed to a liquid state. The cell-containing cryopreservation solution can be evenly applied to the wound surface, injected subcutaneously into the wound, filled into the wound defect, injected into the damaged hair follicle, etc.

[0039] A second aspect of the present invention provides an ITO-containing cell freezing solution.

[0040] A third aspect of the present invention is the use of an ITO-containing cell freezing solution in the preparation of a drug for repairing a wound or a damaged hair follicle.

[0041] It should be noted that the experimental methods used in the present invention are all conventional methods unless otherwise specified; the reagents and materials used are all commercially available unless otherwise specified.

[0042] Example 1 Composition: high glucose medium (70% DMEM) + dimethyl sulfoxide (10% DMSO) + fetal bovine serum (20% FBS) + 1×10 7 / 2ml ITO cells Preparation: Use 7 ml of 1X DMEM, 1 ml of DMSO and 2 ml of FBS, mix thoroughly to obtain 10 ml of freezing solution, filter sterilize at 0.22 μm, and freeze at -20°C for later use.

[0043] Take the successfully separated ITO cells and mix them thoroughly with 2 ml of this group of freezing solution (final concentration 1×10 7 / 2ml), programmed cooling to -80℃, and long-term storage in liquid nitrogen.

[0044] Example 2 Composition: dimethyl sulfoxide (10% DMSO) + fetal bovine serum (90% FBS) + 1×10 7 / 2ml ITO cells Preparation: Use 1 ml DMSO and 9 ml FBS, mix thoroughly to obtain 10 ml freezing solution for later use.

[0045] Take the successfully separated ITO cells and mix them thoroughly with 2 ml of this group of freezing solution (final concentration 1×10 7 / 2ml), programmed cooling to -80℃, and long-term storage in liquid nitrogen.

[0046] Example 3 Cell freezing solution of the present invention (excluding insulin) Ingredients: Complete DMEM + 1.5% sodium carboxymethyl cellulose + 2% propylene glycol + goat liver matrix gel + 1×10 7 / 2ml ITO cells.

[0047] preparation: (1) Under sterile conditions, weigh a certain amount of high-glucose culture medium, add sterile water to a certain volume, and prepare a 4X concentration mixed solution, which is Mix 1; (2) Add an equal volume of 4X concentration propylene glycol (8%) to the 4X concentration mix1 solution to obtain a 2X concentration mix2 solution; (3) Mix 2X concentration of mix2 solution and 2X concentration of sodium carboxymethyl cellulose (3%) and stir until evenly mixed, and adjust the pH value to 6.9-7.2 to obtain 1X concentration of mix3 solution; (4) The Mix 3 solution was sterilized by 0.22 μm filtration, mixed with goat matrix gel, and stored at -80°C until use.

[0048] Take the successfully separated ITO cells and mix them thoroughly with 2 ml of this group of freezing solution (final concentration 1×10 7 / 2ml), programmed cooling to -80℃, and long-term storage in liquid nitrogen.

[0049] Example 4 The cell freezing solution of the present invention (excluding goat liver matrix gel) Ingredients: Complete DMEM + 0.01 mg / ml insulin + 1.5% sodium carboxymethyl cellulose + 2% propylene glycol + 1×10 7 / 2ml ITO cells preparation: (1) Under sterile conditions, weigh a certain amount of high-glucose culture medium, add sterile water to a certain volume, and prepare a 4X concentration mixed solution, which is Mix 1; (2) Add an equal volume of 4X concentration propylene glycol (8%) to the 4X concentration mix1 solution to obtain a 2X concentration mix2 solution; (3) Mix 2X concentration of mix2 solution and 2X concentration of sodium carboxymethyl cellulose (3%) and stir until evenly mixed, and adjust the pH value to 6.9-7.2 to obtain 1X concentration of mix3 solution; (4) Mix 3 solution was sterilized by 0.22 μm filtration and stored at -80°C until use.

[0050] Take the successfully separated ITO cells and mix them thoroughly with 2 ml of this group of freezing solution (final concentration 1×10 7 / 2ml), programmed cooling to -80℃, and long-term storage in liquid nitrogen.

[0051] Example 5 Cell freezing solution 3 of the present invention (excluding sodium carboxymethyl cellulose) Ingredients: Complete DMEM + 0.01 mg / ml insulin + 2% propylene glycol + 1×10 7 / 2ml ITO cells preparation: (1) Under sterile conditions, weigh a certain amount of high-glucose culture medium, add sterile water to a certain volume, and prepare a 4X concentration mixed solution, which is Mix 1; (2) Add an equal volume of 4X concentration propylene glycol (8%) to the 4X concentration mix1 solution to obtain a 2X concentration mix2 solution; (3) Mix the 2X concentration mix2 solution with an equal volume of distilled water and adjust the pH value to 6.9-7.2 to obtain a 1X concentration mix3 solution; (4) The Mix 3 solution was sterilized by 0.22 μm filtration, mixed with goat liver matrix gel, and stored at -80°C until use.

[0052] Take the successfully separated ITO cells and mix them thoroughly with 2 ml of this group of freezing solution (final concentration 1×10 7 / 2ml), programmed cooling to -80℃, and long-term storage in liquid nitrogen.

[0053] Example 6 Cell freezing solution 1 of the present invention (without propylene glycol) Ingredients: Complete DMEM + 0.01 mg / ml insulin + 1.5% sodium carboxymethyl cellulose + 1×10 7 / 2ml ITO cells preparation: (1) Under sterile conditions, weigh a certain amount of high-glucose culture medium, add sterile water to a certain volume, and prepare a 4X concentration mixed solution, which is Mix 1; (2) Add an equal volume of distilled water to the 4X concentration of mix1 solution to obtain a 2X concentration of mix2 solution; (3) Mix 2X concentration of mix2 solution and 2X concentration of sodium carboxymethyl cellulose (3%) and stir until evenly mixed, and adjust the pH value to 6.9-7.2 to obtain 1X concentration of mix3 solution; (4) The Mix 3 solution was sterilized by 0.22 μm filtration, mixed with goat liver matrix gel, and stored at -80°C until use.

[0054] Take the successfully separated ITO cells and mix them thoroughly with 2 ml of this group of freezing solution (final concentration 1×10 7 / 2ml), programmed cooling to -80℃, and long-term storage in liquid nitrogen.

[0055] Example 7 Cell freezing solution 1 of the present invention (complete solution) Ingredients: Complete DMEM + 0.01 mg / ml insulin + 1.5% sodium carboxymethyl cellulose + 2% propylene glycol + goat liver matrix gel + 1×10 7 / 2ml ITO cells preparation: (1) Under sterile conditions, weigh a certain amount of high-glucose culture medium, add sterile water to a certain volume, and prepare a 4X concentration mixed solution, which is Mix 1; (2) Add an equal volume of 4X concentration propylene glycol (8%) to the 4X concentration mix1 solution to obtain a 2X concentration mix2 solution; (3) Mix 2X concentration of mix2 solution and 2X concentration of sodium carboxymethyl cellulose (3%) and stir until evenly mixed, and adjust the pH value to 6.9-7.2 to obtain 1X concentration of mix3 solution; (4) The Mix 3 solution was sterilized by 0.22 μm filtration, mixed with goat liver matrix gel, and stored at -80°C until use.

[0056] Take the successfully separated ITO cells and mix them thoroughly with 2 ml of this group of freezing solution (final concentration 1×10 7 / 2ml), programmed cooling to -80℃, and long-term storage in liquid nitrogen.

[0057] In order to illustrate the construction of the ready-to-use system for separation-freezing-resurrection of liver ITO cells provided by the present invention, further explanation is given in combination with experiments.

[0058] 1.1 Cell experiment: (1) Cell apoptosis experiment: After cell recovery, the cells were centrifuged to obtain the bottom cells, washed with PBS, and double-stained with Annexin V and PI, and detected by flow cytometry.

[0059] (2) Cell activation experiment: Since primary ITO cells spontaneously emit green fluorescence, routine recovery culture was performed and the time for cell fluorescence to disappear was observed under a fluorescence microscope.

[0060] 1.2 Experimental Animals: Male C57 mice weighing 18g-20g were fed adaptively for 7 days before the burn model was established. The burn model was established by scalding the back with a scalder. After removing the hair on the back of the animal, the 2.5 cm 2 The metal probe plate was heated to 150°C, and a 300 g pressure was applied to the mouse back for 10 s to establish a mild burn model. A 500 g pressure was applied to the mouse back for 20 s to establish a severe burn model.

[0061] The burn wounds of the treatment group were subcutaneously injected with 1 ml of different Examples 1-7, and the control group was injected with PBS, and the growth and healing of the wounds of the mice were observed for 5 days. After the experiment, the mice were killed by cervical dislocation.

[0062] See also Figure 1 As shown, the proportion of cells that underwent apoptosis after cell recovery.

[0063] In Examples 1-7, the results of the cell apoptosis experiment using Annexin V and PI double staining indicated that different cell cryopreservation solutions would cause apoptosis of ITO cells, especially Example 5 in which 1.5% sodium carboxymethyl cellulose was removed, which had the highest percentage of cell apoptosis, while Example 7 had the lowest percentage of ITO cell apoptosis. The results indicated that the cell cryopreservation solution of Example 7 had a better effect of maintaining the viability of ITO cells than the traditional cell cryopreservation solution (Examples 1-2) and the cryopreservation solution lacking the core component (Examples 3-6).

[0064] See also Figure 2 As shown, the differentiation time after cell recovery (calculated according to the disappearance of cell autofluorescence + the beginning of the formation of spindle shape) Normally active ITO has the characteristic of spontaneous green fluorescence, which is mainly due to the rich vitamin A in it. By evaluating the maintenance time of green fluorescence, its activation time can be reflected. Studies have found that after the ITO cells in different cell freezing solutions are revived, their self-activation time is also different. Among them, Example 7 is the cell freezing solution in the patent of the present invention, and the ITO cells triggered by it should disappear significantly shorter than other groups. This helps to quickly release a large amount of growth factors required for wound tissue growth during the critical period of wound healing.

[0065] See also Figure 3 Shown is the survival after wound injection (burn wound area) The C57 mouse back burn model was used, and the results showed that the injection of Example 7 could significantly promote wound healing, while the healing time of other groups was significantly prolonged, especially the group injected with only PBS (phosphate solution) had the longest healing time and the largest residual area at the observation time point.

[0066] Table 1: Differences in the ratio of hair follicle growth phase to hair follicle rest phase in mice before and after the intervention of Example 7 in mild burn model and severe burn model

[0067] As can be seen from Table 1, the differences in the ratio of hair follicle growth phase and hair follicle resting phase in mice before and after ITO cell intervention in mild burn models and severe burn models. Compared with the control groups, in both burn models, the ratio of hair follicle growth phase increased significantly and the ratio of hair follicle resting phase decreased significantly after ITO cell intervention.

[0068] Table 2: Differences in serum IL-6 and TGF-β levels before and after cell intervention in Example 7.

[0069]

[0070] As can be seen from Table 2, compared with the WT group, the IL-6 and TGF-β levels in the serum of the Example-1 group and the Example-7 group were increased, which was more conducive to early wound inflammation recovery and late wound healing, and the treatment effect of the Example-7 group was more significant.

[0071] In summary, the present invention optimizes the non-destructive high-purity separation of large mammal liver ITO cells and the development of gel cell cryopreservation solution without allergens, so that high-viability ITO cells can be obtained and directly used for wound treatment by achieving conventional rapid cell rewarming operations, and liver ITO cells are used in the cryopreservation solution to complete ITO cell differentiation and cytokine release, thereby promoting various types of wound repair and hair follicle regeneration. The present invention aims to provide a separation method that is non-damaging to cells, has high separation efficiency, strong operability and low cost, and to provide a new treatment method that promotes wound repair and hair growth by utilizing the natural differentiation characteristics of ITO cells.

[0072] The present invention describes preferred embodiments and their effects. However, those skilled in the art may make additional changes and modifications to these embodiments once they are aware of the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0073] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A method for constructing a ready-to-use system for separation-freezing-recovery of liver ITO cells, characterized in that: The following steps are involved: Highly viable unactivated ITO cells were isolated from mammalian liver; The ITO cells were fully mixed with the ready-to-use cell freezing solution, programmed to cool, and stored in liquid nitrogen; By quickly rewarming the frozen ITO cells to a liquid state, a highly active and unactivated ITO cell suspension can be obtained and directly used for medical treatment; Wherein, the ready-to-use cell freezing solution is prepared according to the following steps: Under sterile conditions, a certain amount of high-glucose culture medium and insulin were weighed, and sterile water was added to a certain volume to prepare a 4X concentration mixed solution, which is the mix1 solution; Add an equal volume of 4X concentration propylene glycol to the 4X concentration mix1 solution to obtain a 2X concentration mix2 solution; Mix 2X concentration of mix2 solution and 2X concentration of sodium carboxymethyl cellulose (3%), and stir to mix evenly, and adjust the pH value to 6.9-7.2 to obtain 1X concentration of mix3 solution; The 1X concentration mix3 solution was sterilized and mixed with an equal volume of liver matrix gel to obtain the target cell freezing solution.

2. The method for constructing a ready-to-use system for lossless separation-freezing-recovery of liver ITO cells according to claim 1, characterized in that: The ITO cells were isolated according to the following steps: Obtain large mammal livers under sterile conditions with preserved portal vein and inferior vena cava; The mammal liver is cannulated in the portal vein in a sterile operating environment, and pre-cooled saline is perfused with heparin. The perfusion is continued to completely remove the red blood cells in the liver until the liver appears yellow-white; The liver without red blood cells was perfused with enzyme digestion solution at 36.5-37.5°C until the liver became soft and inelastic, and then the liver was disrupted in a low-speed blender in a cell dispersion to obtain a liver slurry; The liver slurry was continuously perfused with cells at 3-5°C and filtered, and the filtered suspension was collected; The filtered suspension is centrifuged, resuspended, and the target layer cells are obtained to obtain ITO cells.

3. The method for constructing a ready-to-use system for lossless separation-freezing-recovery of liver ITO cells according to claim 2, characterized in that: The cell suspension is centrifuged, resuspended, and the target layer cells are obtained, including: The filtered suspension was centrifuged at 400-600 rpm / min for 8-12 min, the lower layer of cells was removed and resuspended with D-Hanks solution, then centrifuged at 400-600 rpm / min for 8-12 min, the supernatant was removed, and then centrifuged at 1500-2000 rpm / min for 8-12 min, the lower layer of sediment was removed and resuspended with serum-free DMEM culture medium, and the volume was fixed to obtain a cell suspension; 60% percoll and 30% percoll were added to the bottom of a 50 ml centrifuge tube, and finally the cell suspension was added and centrifuged. In the obtained system, the upper layer of 30% percoll was the obtained ITO cells. 30% or 60% percoll was prepared by adding 10 ml of 10% sodium chloride to 100 ml percoll to make a 100% stock solution, and then using 0.9% saline to make a target concentration of 30% or 60%.

4. The method for constructing a ready-to-use system for separation-freezing-recovery of liver ITO cells according to claim 2, characterized in that: The enzyme digestion solution is prepared by adding type IV collagenase and pronase E to a D-hanks solution, mixing them evenly, adjusting the pH value to 7.0-7.5, and filtering and sterilizing, wherein the mass ratio of type IV collagenase to pronase E is 1:1-2; The cell dispersion is prepared by adding type IV collagenase, pronase E and DNase I to D-hanks solution, mixing evenly and filtering for sterilization, wherein the mass ratio of type IV collagenase, pronase E and DNase I is 8-10:2-4:

1.

5. The method for constructing a ready-to-use system for separation-freezing-recovery of liver ITO cells according to claim 2, characterized in that: The liver matrix gel is prepared according to the following steps: The filtered suspension was centrifuged at 400-600 rpm / min for 8-12 min, the supernatant was taken, and the cell debris was removed by filtration and centrifugation. The liver matrix gel was obtained by low-temperature concentration, and filtered and sterilized for later use.

6. The method for constructing a ready-to-use system for separation-freezing-recovery of liver ITO cells according to claim 1, characterized in that: When preparing the target cell freezing solution, the volume ratio of the high glucose culture medium, insulin, sodium carboxymethyl cellulose and liver matrix gel is 1:1~2:1~2:1~1.5; The concentration of 4X insulin is 0.02~4mg / ml.

7. The method for constructing a ready-to-use system for separation-freezing-recovery of liver ITO cells according to claim 1, characterized in that: 4X high glucose medium was prepared from the following ingredients: Calcium chloride dihydrate 1000~1100mg / L, L-serine 160~170mg / L, ferric nitrate nonahydrate 0.3~0.5mg / L, L-threonine 350~400mg / L, potassium chloride 1500~2000mg / L, L-tryptophan 50~80mg / L, anhydrous magnesium sulfate 350~400mg / L, L-tyrosine 260~300mg / L, sodium chloride 20000~30000mg / L, L-valine 350~400mg / L, anhydrous sodium dihydrogen phosphate 400~450mg / L, D-calcium pantothenate 12~18mg / L, succinic acid 280~320mg / L, choline bitartrate 25.5~30.3mg / L, sodium succinate 380~410mg / L, folic acid 13~18mg / L, L-arginine hydrochloride 310~350mg / L, inositol 26.6~30.3mg / L, L-cystine hydrochloride 160~200mg / L, niacinamide 14~17mg / L, glycine 4500~5000mg / L, riboflavin 6.0~7.0mg / L, L-histidine hydrochloride 150~170mg / L, thiamine hydrochloride 12~20mg / L, L-isoleucine 400~450mg / L, pyridoxine hydrochloride 12~18mg / L, L-leucine 400~450mg / L, glucose 3700~4200mg / L, L-lysine hydrochloride 550~600mg / L, sodium pyruvate 400~450mg / L, L-methionine 100~150mg / L, L-phenylalanine 240~280mg / L.

8. The method for constructing a ready-to-use system for separation-freezing-recovery of liver ITO cells according to claim 1, characterized in that: The concentration of 4X propylene glycol is 8% of the 4X stock solution; the concentration of 2X sodium carboxymethyl cellulose stock solution is 3%. The final concentrations after preparation are 2% and 1.5%, respectively.

9. A cryopreservation solution containing ITO cells obtained by the method according to any one of claims 1 to 8.

10. Use of the ITO-containing cell freezing solution according to claim 9 in the moist healing of wounds or hair follicle damage.